EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models

Syeda Afshan iD, Yu Gang Kim, Jesse Mattsson, Malin Åkerfelt, Pirkko Härkönen, Martin Baumgartner iD, Matthias Nees

Cancer Medicine · 2024

DOI: 10.1002/cam4.70240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Syeda Afshan und 6 weiteren Autor:innen. Beteiligte Einrichtung: FICAN West Cancer Centre, Institute of Biomedicine, University of Turku, Turku, Finland. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Coculture Techniques, Receptors, Fibroblast Growth Factor, Cell Proliferation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Drug Research Doctoral Program of the University of Turku, Finland, the Finnish-Norwegian Medical Foundation/Suomalais-Norjalainen Lääketieteen Säätiö, the Paulo Foundation/Paulon Säätiö, Finland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inhibition of androgen receptor (AR) signaling is the main treatment strategy in advanced prostate cancer (PCa). A subset of castration resistant prostate cancer (CRPC) bypasses the AR blockade by increased fibroblast growth factor receptor (FGFR) signaling. The first‐ and second‐generation, non‐covalent FGFR inhibitors (FGFRis) have largely failed in the clinical trials against PCa.

Purpose

In this study, we tested the drug sensitivity of LNCaP, VCaP, and CWR‐R1PCa cell lines to second‐generation, covalent FGFRis (FIIN1, FIIN2) and a novel FGFR downstream molecule inhibitor (FRS2αi).

Methods

2D and 3D mono‐ and co‐cultures of cancer cells, and cancer‐associated fibroblasts (CAFs) were used to mimic tumor‐stroma interactions in the extracellular matrix (ECM). The treatment responses of the FGFR signaling molecules, the viability and proliferation of cancer cells, and CAFs were determined through immunoblotting, migration assay, cell viability assay, and real‐time imaging. Immunofluorescent and confocal microscopy images of control and treated cultures of cancer cells and CAFs, and their morphometric data were deduced.

Results

The FGFRis were more effective in mono‐cultures of the cancer cells compared with co‐cultures with CAFs. The FRS2αi was specifically effective in co‐cultures with CAFs but was not cytotoxic to CAF mono‐cultures as in the case of FIIN1 and FIIN2. At the molecular level, FRS2αi decreased p‐FRS2α, p‐ERK1/2, and activated apoptosis as monitored by cleaved caspase‐3 activity in a concentration‐dependent manner in the co‐cultures. We observed no synergistic drug efficacy in the combination treatment of the FGFRi with ARi, enzalutamide, and darolutamide. The FRS2αi treatment led to a decrease in proliferation of cancer cell clusters in co‐cultures as indicated by their reduced size and Ki67 expression.

Conclusions

CAFs exert a protective effect on cancer cells and should be included in the in vitro models to make them physiologically more relevant in screening and testing of FGFRis. The FRS2αi was the most potent agent in reducing the viability and proliferation of the 3D organotypic co‐cultures, mainly by disrupting the contact between CAFs and cancer cell clusters. The next‐generation FGFRi, FRS2αi, may be a better alternative treatment option for overcoming ARi treatment resistance in advanced PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer-Associated FibroblastsCoculture TechniquesReceptors, Fibroblast Growth FactorCell ProliferationHumansMaleCell Line, TumorProstatic NeoplasmsSignal TransductionCell SurvivalAntineoplastic Agents

Stichwörter der Autor:innen

AR antagonistFGFR inhibitorsFRS2α inhibitorcancer‐associated fibroblastscastration resistant prostate cancerdarolutamideenzalutamide

Substanzen

Receptors, Fibroblast Growth FactorAntineoplastic Agents

Autor:innen und Institutionen

  • FICAN West Cancer Centre, Institute of Biomedicine, University of Turku, Turku, Finland.
  • Cell Biology, Faculty of Science and Engineering, Åbo Akademi University, Turku, Finland.
  • Pediatric Molecular Neuro-Oncology Research Laboratory, University Children's Hospital Zurich, Zurich, Switzerland.
  • Department of Biochemistry and Molecular Biology, Medical University of Lublin, Lublin, Poland.

ORCID-Profile: Syeda Afshan, Martin Baumgartner

Förderung

  • the Drug Research Doctoral Program of the University of Turku, Finland
  • the Finnish-Norwegian Medical Foundation/Suomalais-Norjalainen Lääketieteen Säätiö
  • the Paulo Foundation/Paulon Säätiö, Finland
  • the Southwest Finland Cancer Organization/Lounaissuomalaiset Syöpäjärjestöt
  • Turku University Foundation/Turun Yliopistosäätiö
  • the European Union's TransPot Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement
  • Research Council of Finland
  • Swiss Cancer Research Foundation

Zitieren

APA

Afshan, S., Kim, Y. G., Mattsson, J., Åkerfelt, M., Härkönen, P., Baumgartner, M., & Nees, M. (2024). Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models. Cancer Medicine. https://doi.org/10.1002/cam4.70240

Vancouver

Afshan S, Kim YG, Mattsson J, Åkerfelt M, Härkönen P, Baumgartner M, et al. Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models. Cancer Medicine. 2024. doi:10.1002/cam4.70240

BibTeX
@article{Afshan2024,
  author = {Afshan, Syeda and Kim, Yu Gang and Mattsson, Jesse and Åkerfelt, Malin and Härkönen, Pirkko and Baumgartner, Martin and Nees, Matthias},
  title = {Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70240}
}
Kostenlos starten →